Core Viewpoint - Yong'an Pharmaceutical (002365) announced that its actual controller and chairman, Chen Yong, has had the detention measures lifted by the Hekou County Supervisory Committee, allowing him to resume his duties as chairman of the company [1] Company Summary - The company has confirmed that Chen Yong is now able to perform his responsibilities as chairman, indicating a return to normalcy in its operations [1] - Chen Zidong will no longer act as the interim chairman, as Chen Yong has resumed his role [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced that its actual controller and chairman, Mr. Chen Yong, has had the detention measures lifted by the Hekou County Supervisory Committee, allowing him to resume his duties as chairman of the company [1] Company Operations - The company is currently operating normally following the lifting of the detention measures against Mr. Chen Yong [1] - Mr. Chen Zidong will no longer act on behalf of Mr. Chen Yong as the chairman [1]

Core Points - The actual controller and chairman of the company, Chen Yong, was previously under investigation by the Hefeng County Supervisory Committee, which has now been lifted, allowing him to resume his duties [1] Company Situation - The company announced that Chen Yong was placed under investigation on May 6, and the recent notification from his family indicates that the supervisory measures have been removed [1] - The company’s production and operational status is reported to be normal following the resolution of the investigation [1]

智通财经APP讯，永安药业(002365.SZ)公告，公司实际控制人、董事长陈勇先生此前被鹤峰县监察委员 会立案调查并实施留置。近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解除 留置通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。 ...

特此公告。 潜江永安药业股份有限公司 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 5 月 6 日披露 《关于公司实际控制人、董事长被留置的公告》（公告编号：2025-31），公司 实际控制人、董事长陈勇先生被鹤峰县监察委员会立案调查并实施留置。 近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解 除留置通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。目前，陈勇 先生已能正常履行公司董事长的职责，公司生产经营情况正常。陈子笛先生将不 再代为履行公司董事长的职责。 证券代码：002365 证券简称：永安药业 公告编号：2025-50 公司指定信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》 和巨潮资讯网，公司发布的信息均以在上述媒体刊登的公告为准。敬请广大投资 者注意投资风险。 关于公司实际控制人、董事长解除留置的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司 董 事 会 二〇二五年九月三日 ...

永安药业（002365）(002365.SZ)公告，公司实际控制人、董事长陈勇先生此前被鹤峰县监察委员会立 案调查并实施留置。近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解除留置 通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。 ...

Core Viewpoint - The performance of the Zhongzheng 2000 ETF Enhanced (159556) has shown a decline of 2.20% as of the midday close on September 2, with a trading volume of 2.0863 million yuan [1] Group 1: Fund Performance - The Zhongzheng 2000 ETF Enhanced (159556) has a performance benchmark based on the Zhongzheng 2000 Index return [1] - Since its establishment on December 27, 2023, the fund has achieved a return of 18.85% [1] - The fund's return over the past month is reported at 9.45% [1] Group 2: Major Holdings - Major stocks in the fund include: - Zhenhua New Materials, down 1.72% - Hengbao Co., down 8.57% - Yongding Co., down 6.21% - Yong'an Pharmaceutical, down 2.03% - Xuguang Electronics, down 1.07% - Zhongke Technology, down 1.89% - Juguang Technology, down 3.61% - Huitong Energy, down 2.42% - Xinke Materials, down 2.41% - Batian Co., down 3.71% [1]

Group 1 - The graphite electrode sector saw a rise of 2.32%, ranking third among concept sectors, with 12 stocks increasing in value, including Puxin Technology, Shantai Technology, and Suotong Development reaching their daily limit [1][2] - Notable gainers included Zhongke Electric, Bettery, and China Baowu, which rose by 14.59%, 13.58%, and 3.70% respectively [1] - The sector experienced a net outflow of 0.11 billion yuan in main funds, with 8 stocks receiving net inflows, and 7 stocks seeing inflows exceeding 10 million yuan [2][3] Group 2 - The top net inflow was recorded for Suotong Development, with a net inflow of 324 million yuan, followed by Shantai Technology and Puxin Technology with net inflows of 220 million yuan and 205 million yuan respectively [2][3] - The net inflow ratios for Shantai Technology, Suotong Development, and Puxin Technology were 21.42%, 19.39%, and 11.52% respectively [3] - The stocks with the largest declines included Guomin Technology, Yong'an Pharmaceutical, and Huajin Co., which fell by 3.42%, 1.72%, and 1.50% respectively [1][4]

Financial Performance - The company reported a significant decline in net profit, down 76.19% year-on-year, with a total revenue of 367 million yuan, a decrease of 13.72% compared to the previous year [1] - The gross margin fell to 15.81%, a decrease of 40.14%, while the net margin dropped to 2.33%, down 80.6% year-on-year [1] - In the second quarter, total revenue was 196 million yuan, down 14.38%, and net profit was 16.86 million yuan, a decline of 29.16% [1] Key Financial Metrics - The company's operating expenses, including sales, management, and financial costs, totaled 42.14 million yuan, accounting for 11.47% of revenue, an increase of 1.25% year-on-year [1] - Earnings per share decreased to 0.04 yuan, down 75.74% year-on-year, while operating cash flow per share increased by 62.58% to 0.17 yuan [1] - The company’s return on invested capital (ROIC) was reported at 2.86%, indicating weak capital returns over recent years [3] Business Strategy and Outlook - The company plans to maintain its position as a traditional taurine supplier while also focusing on developing its own brand products in the health and consumer goods market [4] - The management expressed confidence in the taurine market, citing a strong foundation built over 20 years and readiness to capitalize on macroeconomic policies aimed at expanding domestic demand [3][4] - The company emphasizes the importance of its marketing-driven business model and the need to monitor accounts receivable, which currently stands at 182.19% of profits [3]

Group 1 - The core viewpoint of the article highlights that Yong'an Pharmaceutical (002365.SZ) reported a significant decline in both revenue and net profit for the first half of 2025 [1] Group 2 - The company achieved an operating income of 367 million yuan, representing a year-on-year decrease of 13.72% [1] - The net profit attributable to shareholders of the listed company was 12.4957 million yuan, down 76.19% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2.2853 million yuan, a decrease of 93.65% year-on-year [1] - The basic earnings per share were 0.0432 yuan [1]